Thank you for taking the time to enter your patient's information. This survey is designed to capture initial information about ALL pediatric patients with COVID-19 in the United States. Please complete the following survey in as much detail as possible.

Please do not enter any patient identifiers in the survey (e.g., names, initials, dates, etc.).

For questions or comments related to the survey or study, please contact PIDTRANCoordinators@stjude.org.

Study ID

Is this patient less than 21 years old with a new diagnosis of COVID-19?

⊖ Yes ⊖ No



Please select one of the following	 General Pediatric Patients (Patients in this group may be otherwise healthy or have underlying co-morbidities such as heart or lung disease. A patient who has not previously received a transplant or cellular therapy and is not otherwise immunocompromised.) A hematopoietic cell transplant (HCT) or cellular therapy (CT) recipient A solid organ transplant (SOT) recipient An immunocompromised patient who has NOT received a HCT, CT or SOT (For patients who received both SOT and HCT/CT, select the most recent transplant.)
If HCT or CT recipient, did the patient also receive a SOT within the past year?	○ Yes ○ No ○ Does not apply



Patient Information

Please complete the following demographic information about your patient as well as the site contact information for the person submitting this survey. We will use this contact information to notify you within 30 days when the COVID-19 case follow-up forms are due.

The unique Subject ID for this patient is	
[record-name]	
Please record this Subject ID and maintain the I coordinating center that the link can be destroy Subject ID to reference your patient since no PH	ed. The coordinating center will use the
Age (in years) at time of COVID-19 diagnosis.	
For patients less than 1 year of age, divide age in month by 12.	(Date of COVID-19 diagnosis is the date initial specimen positive for COVID-19 was collected from the patient.)
Sex	 Male Female Unknown Other
Race (Check all that apply)	 Asian American Indian/ Alaska Native Black or African American Native Hawaiian/ Other Pacific Islander White or Caucasian Unknown Other
Other specified race	
Ethnicity	 Hispanic/Latino Not specified Non-Hispanic/Latino
Treating institution/hospital	



State of treating institution/hospital

- \bigcirc US Armed Forces Europe
- O Alaska
- 🔿 Alabama
- US Armed Forces Pacific
- \bigcirc Arkansas
- American Samoa
- ⊖ Arizona
- 🔿 California
- \bigcirc Colorado
- Connecticut ○ Washington, D.C.
- ⊖ Delaware
- ⊖ Florida
- Federated States of Micronesia
- ⊖ Georgia
- ⊖ Guam
- 🔿 Hawaii
- 🔿 lowa
- O Idaho
- Illinois
- Indiana ○ Kansas
- Kentucky ○ Louisiana
- Massachusetts
- Maryland
- Maine
- Marshall Islands
- Michigan
- Minnesota
- ⊖ Missouri
- O Northern Mariana Islands
- ⊖ Mississippi
- O Montana
- O North Carolina
- North Dakota Nebraska
- New Hampshire
- O New Jersey
- O New Mexico
- \bigcirc Nevada
- New York
- ⊖ Ohio
- 🔿 Oklahoma
- O Oregon
- O Pennsylvania O Puerto Rico
- 🔿 Palau
- Rhode Island ○ South Carolina
- South Dakota
- ⊖ Tennessee
- ⊖ Texas
- 🔿 Utah
- Virginia
- Virgin Islands
- ⊖ Vermont
- Washington
- ⊖ Wisconsin
- O West Virginia ⊖ Wyoming
- \bigcirc NA



City of treating institution/hospital

Contact person for follow-up questions

Contact e-mail

(Follow-up questions and correspondence will be sent to the email provided above.)



Hematopoietic Cell Transplant Patient

Please complete the following information about the patient who received HCT and/or CT.

You can use the [survey-queue-link:survey queue button] at the top right of the screen to navigate back to previous forms if needed.

The unique Subject ID for this patient is

[record-name]

Please record this Subject ID and maintain the link to your patient until notified by the coordinating center that the link can be destroyed. The coordinating center will use the Subject ID to reference your patient since no PHI maybe shared outside of your institution.

Day 0 is defined as the collection date of the initial positive COVID-19 diagnostic test.

Underlying diagnosis at the time of COVID-19 diagnosis	 Brain tumor Solid tumor Hematologic disorder Hematologic malignancy Inherited immunodeficiency Other underlying diagnosis
	 Aplastic anemia Sickle cell disease Other
	 Acute Lymphocytic Leukemia (ALL) Myelodysplastic Syndrome (MDS) Acute Myelogenous Leukemia (AML) Hodgkin's Lymphoma Acute Promyelocytic Leukemia (APL) Non-Hodgkin's Lymphoma Other Leukemia Other
	 Severe Combined Immunodeficiency (SCID) Wiskott-Aldrich syndrome Other

Please specify



Other medical conditions (select all that apply)	
 Cardiac Renal Hepatic/GI Neurological Endocrine Other No other medical conditions 	
If Cardiac, specify	
If Renal, specify	
If Hepatic/GI, specify	
If Neurologic, specify	
If Endocrine, specify	
If other medical condition, specify	
Patient has chronic lung disease	○ Yes ○ No
If chronic lung disease, specify	 Asthma/active airway disease Pulmonary hypertension Congenital pulmonary anomaly Bronchopulmonadry dysplasia Cystic fibrosis Other
If other, please specify	
Is the patient receiving any of the following? (Check all that apply)	ACE Inhibitor ARB NSAID



Most recent treatment for underlying diagnosis prior to COVID-19 diagnosis?	 Cellular therapy (e.g., CART) - patients undergoing CT with or without preceding HCT Hematopoetic Cell Transplant - Patients undergoing HCT or HCT following CT (e.g., CART).
Days since most recent transplant or cellular therapy at Day 0.	 1 to 30 days 31 to 100 days 101 days to 180 days 181 to 365 days 1 to 2 years > 2 years Unknown
Most recent transplant or cellular therapy number.	 First Second Third Fourth Fifth Unknown
Please answer the following questions about th	e patients most recent HCT.
Type of transplant	 Allogeneic Autologous HCT
If Allogeneic, type of source	 Matched sibling donor (MSD) Matched unrelated donor (MUD) Mismatch unrelated donor Haploidentical Other Unknown
lf Other, specify	
Source of transplant	 Umbilical cord Bone marrow Peripheral blood (PBMC) Unknown
Conditioning regimen	 Myeloablative Non-myeloablative Reduced intensity conditioning Unknown
Lymphocyte depletion (Check all that apply)	 T-cell depletion B-cell depletion None (T cell depletion defined as manipulation of donor cells before infusion by either CD34+ enrichment, CD3+ depletion, TCR[]] depletion or CD45RA depletion)
At the time of COVID-19, did the patient have GvHD?	 ○ Yes, Acute GvHD ○ Yes, Chronic GvHD ○ No

REDCap

Was the patient receiving treatment for GvHD?	○ Yes ○ No
Was the patient receiving GvHD or rejection prophylaxis (other than steroids)?	○ Yes ○ No
Did the patient receive systemic steroids in the 14 days prior to Day 0?	 Yes No (Systemic steroids include Prednisone, prednisolone, methylprednisolone, or dexamethasone.
Highest systemic steroids daily dose in 2 weeks prior to COVID-19 presentation (As Prednisolone equivalent)	○ < 1 mg/kg ○ 1-2 mg/kg ○ > 2 mg/kg ○ Dose unknown
Transplant/treatment related outcomes at Day 0? (Select all that apply)	 Secondary malignancy Graft failure Relapse of primary disease Other None of the above
If Other, specify	
Is the patient receiving treatment for relapsed malignancy?	○ Yes ○ No
malignancy?	
malignancy? Please answer the following questions about th	CART CART Investigational TCRs TIL protocol Other
Please answer the following questions about th Most recent cellular therapy type	CART CART Investigational TCRs TIL protocol Other
malignancy? Please answer the following questions about the Most recent cellular therapy type If Other, specify	CART CART CINVESTIGATIONAL TCRS TIL protocol Other Unknown CD19 CD20 BCMA ROR1 Other target
malignancy? Please answer the following questions about the Most recent cellular therapy type If Other, specify Most recent cellular therapy target	CART CART CINVESTIGATIONAL TCRS TIL protocol Other Unknown CD19 CD20 BCMA ROR1 Other target



Immunocompromised Patient

Please complete the following questions about the immunocompromised patient.

You can use the [survey-queue-link:survey queue button] at the top right of the screen to navigate back to previous forms if needed.

The unique Subject ID for this patient is

[record-name]

Please record this Subject ID and maintain the link to your patient until notified by the coordinating center that the link can be destroyed. The coordinating center will use the Subject ID to reference your patient since no PHI maybe shared outside of your institution.

Any pre-existing medical conditions o co-morbidities?	r	○ Yes ○ No ○ Ur	nknown
	Yes	No	Unknown
Pulmonary	\bigcirc	0	\bigcirc
Chronic lung disease	\bigcirc	0	\bigcirc
Cardiac	\bigcirc	0	\bigcirc
Cardiovascular disease	\bigcirc	0	\bigcirc
Heart failure	\bigcirc	0	\bigcirc
Pulmonary hypertension	\bigcirc	0	\bigcirc
Renal	\bigcirc	0	\bigcirc
Chronic kidney disease	\bigcirc	\bigcirc	\bigcirc
Renal failure	\bigcirc	\bigcirc	\bigcirc
Gastrointestinal/Hepatology	\bigcirc	\bigcirc	0
Liver disease	\bigcirc	\bigcirc	\bigcirc
Liver failure	\bigcirc	\bigcirc	\bigcirc
Endocrine	\bigcirc	\bigcirc	\bigcirc
Neurologic/neurodevelopmental/ intellectual disability	0	0	0
Other diseases	0	0	0

If Other chronic diseases, specify



What is the subject's immunocompromising condition	 Acquired immunodeficiency / HIV Bone marrow failure Cancer - Leukemia or lymphoma Cancer - Solid tumor (including CNS tumor) Primary immunodeficiency Rheumatological/inflammatory condition
Select the subject's specific leukemia or lymphoma condition	 Acute lymphoid leukemia (ALL) Acute myeloid leukemia (AML) Chronic myeloid leukemia (CML) Myelodysplastic syndromes (MDS) Non-Hodgkin lymphoma Hodgkin's lymphoma Other leukemia/lymphoma
Specify the leukemia or lymphoma condition not listed above	
Select the subject's specific solid tumor	 Brain tumor Bone/soft tissue sarcoma Hepatoblastoma Neuroblastoma Retinoblastoma Wilm's tumor Other solid tumor
Specify the solid tumor not listed above	
Has the patient recently received (in the past month) or is the child currently receiving chemotherapy or immune therapy for cancer?	 ○ Yes ○ No ○ Unknown
Select the primary intention of the recent chemotherapy	 Immunotherapy Initial induction treatment for any cancer, consolidation therapy, delayed intensification, or any chemotherapy course that results in prolonged neutropenia Maintenance chemotherapy
Select the subject's specific primary immunodeficiency	 Chronic granulomatous disease Common variable immune deficiency Complement deficiency Severe combined immune deficiency X-linked agammaglobulinemia Other primary immunodeficiency
Specify the primary immunodeficiency not listed above	
Select the subject's specific bone marrow failure condition	 Aplastic anemia Kostmann Syndrome Neutropenia syndromes Other red cell disorders Thalassemia Other
Specify the bone marrow failure condition not listed above	



Select the subject's specific rheumatological/inflammatory condition	 Dermatomyositis Inflammatory bowel disease JIA Lupus Psoriasis Other
Specify the subject's rheumatological/inflammatory condition not listed above	
Select the subject's specific acquired immunodeficiency	○ HIV○ Other
Specify the subject's acquired immunodeficiency not listed above	
Is the patient currently on highly active anti-retroviral therapy?	 ○ Yes ○ No ○ Unknown
If currently on highly active anti-retroviral therapy, does the therapy include Kaletra?	 ○ Yes ○ No ○ Unknown
Is the patient currently receiving an ACE inhibitor?	 ○ Yes ○ No (Benazepril, Captopril,Enalapril, Fosinopril, Lisinopril, Moexipril, Quinapril, Ramipril)
During the past 28 days, was the patient on any o	of the following classes of
immunosuppressives?	
Steroids	○ Yes ○ No
Select the steroid(s) taken during the past 28 days	 Dexamethasone Methylprednisolone Prednisolone Prednisolone Prednisone
Anti-cytokine/cytokine receptors	○ Yes ○ No



Select the anti-cytokine(s) or cytokine receptor(s) taken during the past 28 days	 Adalimumab Anakinra Basiliximab Cankinumab Cankinumab Certolizumab pegol Daclizumab Emapalumab Etanercept Golimumab Infliximab Ixekizumab Rilonacept Secukinumab Siltuximab Tadekinig Tocilizumab Ustekinumab
Antimetabolites/anti-proliferatives	○ Yes ○ No
Select the antimetabolite(s) or anti-proliferative(s) taken during the past 28 days	 Azathioprine Leflunomide Methotrexate Mycophenolate mofetil
Calcineurin inhibitors	○ Yes ○ No
Select the calcineurin inhibitor(s) taken during the past 28 days	☐ Cyclosporine ☐ Tacrolimus
mTOR inhibitors	○ Yes ○ No
Select the mTOR inhibitor(s) taken during the past 28 days	 Everolimus Sirolimus
Other monoclonals/biologics	○ Yes ○ No
Select the other monoclonal(s) or biologic(s) taken during the past 28 days	 ☐ Abatacept ☐ Alemtuzumab ☐ Eculizumab ☐ Ofatumumab ☐ Rituximab
JAK inhibitors	○ Yes ○ No
Select the JAK inhibitor(s) taken during the past 28 days	 □ Baricitinib □ Ruxolitinib □ Tofacitinib
Hydroxychloroquine	○ Yes ○ No



Other immunosuppressives	○ Yes ○ No
Select the other immunosuppressives taken during the past 28 days	□ ATG □ Bortezomib
Other immunosuppressives not listed on this page	○ Yes ○ No
List all other immunosuppressives not listed on this page which were taken in the last 28 days	



Please complete the following health questions about the patient.

You can use the [survey-queue-link:survey queue button] at the top right of the screen to navigate back to previous forms if needed.

The unique Subject ID for this patient is

[record-name]

Please record this Subject ID and maintain the link to your patient until notified by the coordinating center that the link can be destroyed. The coordinating center will use the Subject ID to reference your patient since no PHI maybe shared outside of your institution.

Select underlying diagnosis or co-morbidity	
(Check all that apply)	

Pulmonary
Cardiac
Neurologic
GI/Hepatology
Renal
Hematologic
Endocrine
Other

Specify Pulmonary co-morbidity (Check all that apply)	 Asthma Pulmonary hypertension Congenital pulmonary anomaly Bronchopulmonary dysplasia Cystic fibrosis Tracheostomy dependence Ventilator dependence Other
If Other, specify	
Is this patient on home non-invasive ventilation?	⊖ Yes ⊖ No
Specify Cardiac co-morbidity (Check all that apply)	 Congenital cardiac disease Cardiomyopathy Heart failure Pulmonary hypertension Lymphatic disorder Other
If Other, specify	



Specify Neurologic co-morbidity (Check all that apply)	 Hypoxic-ischemic encephalopathy Neurodegenerative disease Seizure disorder Other
lf Other, specify	
Specify Gastrointestinal/Hepatology co-morbidity (Check all that apply)	 G-tube/G-J tube dependence TPN dependence History of bilary atresia History of short gut syndrome Other
lf Other, specify	
Specify Renal co-morbidity (Check all that apply)	 Nephrotic syndrome Chronic Kidney Disease Dialysis dependence Other
lf Other, specify	
Specify Hematologic co-morbidity (Check all that apply)	 ☐ Sickle cell disease ☐ Hemophilia ☐ Other
lf Other, specify	
Specify Endocrine co-morbidity (Check all that apply)	 Diabetes mellitus Adrenal insufficiency Other
If Other, specify	
If other, specify	



Is this patient on any of the following medications?

- Regular inhaled corticosteroids
- Regular physiologic replacement of steroids
- Regular systemic steroids (dexamethasone, methylprednisolone, prednisolone, prednisone)
- mTOR inhibitors (sirolimus, everolimus)
- Hydroxychloroquine
- Antimetabolites/anti-proliferatives (azathioprine, leflunomide, methotrexate, mycophenolate mofetil)
- TNF-a inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab)
- Other monoclonals/biologics (abatacept, alemtuzumab, anti-CD20s, basiliximab, eculizumab, ustekinumab)
- Calcineurin inhibitors (cyclosporine, tacrolimus)
- JAK inhibitors (tofacitnib, baracitnib, ruxolitnib)
- Other
- No medications being taken

If Other, specify

Additional pertinent medical history



The COVID-19 survey for pediatric patients who have received SOT is coordinated by the University of Washington. You will redirected to that survey after clicking submit below.

For questions, please contact Olivia Kates at okates@uw.edu.



COVID-19 Case Information

Please complete the following information about the patient's COVID-19 case.

This asks for information for the first 7 days from date of first positive COVID-19 test, so please finalize only if patient has reached Day 7. If you wish complete this survey at a later time, submit this form and follow the link provided in the email to return to the survey.

You can use the [survey-queue-link:survey queue button] at the top right of the screen to navigate back to previous forms if needed.

The unique Subject ID for this patient is

[record-name]

Please record this Subject ID and maintain the link to your patient until notified by the coordinating center that the link can be destroyed. The coordinating center will use the Subject ID to reference your patient since no PHI maybe shared outside of your institution.

Unless noted in the questions, the following questions apply to 72 hours prior to and 7 days after Day 0.


Day 0 is defined as the collection date of first positive COVID-19 diagnostic test.

Source of positive COVID-19	laboratory testing
(Check all that apply)	

Nasal
Stool
BAL
Tracheal aspirate
Blood
Nasopharyngeal
Oropharyngeal
Expectorated sputum
Lung biopsy
Other

If Other, please specify

Any of the following exposures or risk for COVID-19? (check all that apply):





If other exposure, specify	
Did the patient have any symptoms that initiated COVID-19 testing?	⊖ Yes ⊃ No
Symptoms	
Did the patient have any signs or symptoms from - 72 hours to Day 0?	\bigcirc Yes \bigcirc No (Day 0 is defined as the collection date of first positive Covid-19 diagnostic test.)

If Yes, please review the following symptoms and check if were present at any point from -72 hours to Day 0.

(Day 0 is defined as the collection date of first positive Covid-19 diagnostic test.)

	Yes	No	Unknown
Fever >100.4F (38C)	\bigcirc	\bigcirc	0
Muscle aches (myalgia)	\bigcirc	0	0
Rash	\bigcirc	0	\bigcirc
Headache	\bigcirc	0	0
Eye redness (conjunctivitis)	\bigcirc	0	\bigcirc
Runny nose (rhinorrhea)	\bigcirc	0	\bigcirc
Sore throat	\bigcirc	0	0
Cough (new onset or worsening of chronic cough)	0	0	0
Dry Cough	\bigcirc	0	0
Productive cough	\bigcirc	0	\bigcirc
Bloody sputum (hemoptysis)	\bigcirc	0	\bigcirc
Shortness of breath (dyspnea)	\bigcirc	0	\bigcirc
Wheezing	\bigcirc	0	\bigcirc
Apnea	\bigcirc	0	\bigcirc
Chest pain	\bigcirc	0	\bigcirc
Abdominal pain	\bigcirc	0	\bigcirc
Nausea	\bigcirc	0	\bigcirc
Vomiting	\bigcirc	0	\bigcirc
Diarrhea (>3 loose/looser than normal stools/24hr period)	0	0	0
Seizures	0	0	0
Loss of taste and/or smell	\bigcirc	0	\bigcirc



Did the patient have any signs or symptoms reported between Day 1 and Day 7?

🔿 Yes 🔿 No
Day 0 is defined as the collection date of first
oositive Covid-19 diagnostic test.)

If Yes, please select the days each sign or symptom was reported. If it was not reported									
anytime between Day 1 and	l Day 7, s	select No	t Report	ed.					
(Day 0 is defined as the collection date of first positive Covid-19 diagnostic test.)									
	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7	Not Reported	
Fever >100.4F (38C)									
Muscle aches (myalgia)									
Rash									
Headache									
Eye redness (conjunctivitis)									
Runny nose (rhinorrhea)									
Sore throat									
Cough (new onset or worsening of chronic cough)									
Dry Cough									
Productive cough									
Bloody sputum (hemoptysis)									
Shortness of breath (dyspnea)									
Wheezing									
Apnea									
Chest pain									
Abdominal pain									
Nausea									
Vomiting									
Diarrhea (>3 loose/looser than normal stools/24hr period)									
Seizures									

Chest X-ray


Was a chest x-ray performed on Day 0 or in the 72 hours prior to Day 0?

- \bigcirc Yes with Normal findings
- Yes with Abnormal findings
 Not performed
- O Unknown

(Day 0 is defined as the collection date of first positive Covid-19 diagnostic test.)



Select which abnormal fine	dings wer	e reporte	ed below	at any p	oint from	n -72 hou	rs to Da	y 0.	
(Day 0 is defined as the collection date of first positive Covid-19 diagnostic test.)									
		Yes		N			Unknown		
Lobar consolidation		0		C)		0		
Multifocal or patchy opacity				C)		0		
Interstitial infiltrates		\bigcirc		C)		\bigcirc		
Bronchial or peribronchial thickening/cuffing		0 0 0							
		and David	70			fin el in ene			
Was a chest x-ray performed between Day 1 and Day 7? Yes - with Abnormal findings Yes - with Abnormal findings Not performed Unknown (Day 0 is defined as the collection date of first positive Covid-19 diagnostic test.)									
	Select the day(s) each finding was reported. (Day 0 is defined as the collection date of first positive Covid-19 diagnostic test.)								
	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7	Not Reported	
Lobar consolidation									
Multifocal or patchy opacity									
Interstitial infiltrates									
Bronchial or peribronchial thickening/cuffing									
Chest CT									
Was a CT performed on Day 0 or in the 72 hours prior to Day 0?				 Yes - wit Yes - wit Not perf Unknow (Day 0 is d positive Co 	h Abnorma ormed n efined as t	al findings the collection	on date of t.)	first	





Select which abnormal findings were reported below at any point from -72 hours to Day 0.									
(Day 0 is defined as the co	llection d	ate of fir	st positiv	ve Covid-	19 diagr	ostic tes	st.)		
		Yes		N	0		Unknow	'n	
Lobar consolidation		\bigcirc		C)		\bigcirc		
Multifocal or patchy opacity or ground glass opacity		0		C	\supset		0		
Interstitial infiltrates		\bigcirc		\subset	$\mathbf{)}$		\bigcirc		
Nodule(s)	0 0						\bigcirc		
Bronchial or peribronchial thickening/cuffing		0		0					
Tree-in-bud opacities		\bigcirc		C	$\mathbf{)}$		0		
Was a CT performed at between Day 1 and Day 7? Was a CT performed at between Day 1 and Day 7? Yes - with Abnormal findings Not performed Unknown (Day 0 is defined as the collection date of first positive Covid-19 diagnostic test.)									
Select the day(s) each find	ing was r	eported.							
	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7	Not Reported	
Lobar consolidation									

Multifocal or patchy opacity or ground glass opacity				
Interstitial infiltrates				
Nodule(s)				
Bronchial or peribronchial thickening/cuffing				
Tree-in-bud opacities				

Location of respiratory illness at Day 0 per clinician evaluation (Day 0 is defined as the collection date of first positive Covid-19 diagnostic test.)

Upper respiratory tract infection (URTI)
 Lower respiratory tract infection(LRTI)

Laboratory findings, Weights, & Measures at the time of onset (nearest to Day 0) Day 0 is defined as the collection date of first positive Covid-19 diagnostic test. WBC (x 10³/mm) ALC ANC Body Mass Index (BMI) (For children 2 years of age or older.) Were any co-pathogens detected in blood or \bigcirc Yes \bigcirc No respiratory samples within 72 hours prior to and 7 (Day 0 is defined as the collection date of first days after positive COVID-19 test? positive Covid-19 diagnostic test.) If Yes, please list below (separate pathogens with a semicolon) COVID-19 related hospitalization within 7 days of Day ⊖ Yes ⊖ No 0? (Day 0 is defined as the collection date of first positive Covid-19 diagnostic test.) If Yes, what Day after Day 0 was the patient admitted? (Day 0 is defined as the collection date of first positive Covid-19 diagnostic test.) COVID-19 related ICU admission within 7 days of Day \bigcirc Yes \bigcirc No (Day 0 is defined as the collection date of first 0? positive Covid-19 diagnostic test.) If Yes, what Day after Day 0 was the patient admitted to the ICU? (Day 0 is defined as the collection date of first positive Covid-19 diagnostic test.) Did patient require baseline oxygen prior to onset of ○ Yes ○ No COVID-19? Did they patient have any oxygen requirements up to ○ Yes \bigcirc No Day 7. (Supplemental oxygen use was defined as the delivery of oxygen by any modality, including (Day 0 is defined as the collection date of first nasal cannula, mask, noninvasive positive positive Covid-19 diagnostic test.) pressure ventilation, or mechanical ventilation, and was recorded if sustained for >4 hours for each day. If patients received oxygen support as baseline given their underlying diseases, only supplemental oxygen use beyond their baseline requirements will be counted.)



Select the day(s) when each oxygen requirement was given. If it intervention was not administered or it is unknown if it was given select "Not Given".									
	Day 0	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7	Not
Nasal cannula High flow BIPAP/CPAP Mask Mechanical Ventilation Other									given
lf Other, please describe									
Did the patient receive any COVID (Day 0 is defined as the collection									
○ Yes ○ No									
Please check the therapies that th	e patient	received	between	Day 0 an	d Day 7. S	Select all	that apply	<i>.</i>	
(Day 0 is defined as the collection	date of f	irst positiv	ve Covid-:	19 diagno	stic test.)			
 LPV/RTV Hydroxycholorquine Interferon Ribavirin Remdesivir Azithromycin Tocilizumab Darunavir/Cobicistat Siltuximab Anakinra Other 									
lf Other, specify									
Did the patient receive steroid tre COVID-19 between Day 0 and Day	7?			(Day		ed as the	collection ostic test.		irst
If Yes, select which steroids the pa (Check all that apply)	atient rec	eived		🗌 De	drocortiso xamethas thylpredn her	one			
If Other, specify									



Was IVIG administered within 72 hours before Day 0 to 7 days (Day 0 is defined as the collection date of first positive Covid-	
 No Yes - for treatment of COVID-19 Yes - for supplemental purposes Yes - administered, but for unclear indication 	
Did the patient progress to LRTI within 7 days of Day 0?	 ○ Yes ○ No ○ Unknown (Day 0 is defined as the collection date of first positive Covid-19 diagnostic test.)
If Yes, how many days after Day 0 did the patient progress to LRTI?	(Day 0 is defined as the collection date of first positive Covid-19 diagnostic test.)
Did the patient have other complications within 7 days of Day 0?	\bigcirc Yes \bigcirc No (Day 0 is defined as the collection date of first positive Covid-19 diagnostic test.)
Specify complications	
Maximum Severity of illness from Day 0 to Day 7	 Mild (No need for supplementary oxygen) Moderate (Need for supplementary oxygen) Severe (Need for mechanical ventilation) (Day 0 is defined as the collection date of first positive Covid-19 diagnostic test.)
Did the patient die within 7 days of Day 0?	\bigcirc Yes \bigcirc No (Day 0 is defined as the collection date of first positive Covid-19 diagnostic test.)
If Yes, was death COVID-19 related?	○ Yes ○ No ○ Unclear etiology
If Yes, what was the cause of death?	 Respiratory failure Myocarditis Other Unknown
lf Other, please specify	

How many days after Day 0 did patient die?

 $\overline{(\text{Day 0 is defined as the collection}}$ date of first positive Covid-19 diagnostic test.)



COVID-19 Case Follow-Up

The unique Subject ID for this patient is

[record-name]

Please record this Subject ID and maintain the link to your patient until notified by the coordinating center that the link can be destroyed. The coordinating center will use the Subject ID to reference your patient since no PHI maybe shared outside of your institution.

REDCap Follow-up Survey

